Choose your best clinical trial scenario
CANscript provides a human system to gather relevant, heterogeneous human data to inform and optimize your clinical design for first in-human studies.
Improve the chance of clinical success while simultaneously reducing the risk of clinical failure.
Understand efficacy potential in a diversity of samples by testing compounds and combinations in a recapitulative tumor microenvironment model that includes the immune compartment
Test more relevant tissue types combined with a faster and more economic approach to define patient cohorts
Data-driven approach to defining potential of clinical efficacy that considers beyond genomic approaches and relies on phenotypic endpoints
Get access to a biomarker platform from lead optimization to co-clinical trials
Clinical trials meets ex vivo
Each patient’s cancer is unique. Testing drug candidates in a system that reflects the complexity of clinical patients is critical to increasing clinical success. CANscript uniquely preserves the heterogeneity of patient tumors for relevant environment testing.
Customize your clinical trial study design for targeted scientific questions across single agent or combination therapeutic strategies.
Define the population in which drug candidates will have the most success
Coupled with exploratory assays, CANscript offers a platform to elucidate patient populations with the ability to interrogate multiple and combination therapies in the same patient samples.
Establish convincing evidence of your drug candidates’ clinical efficacy, lowering the risk of program failure.
CANscript provides a consistent and scalable human system to enable biomarker development along the drug development pipeline. The platform’s unique versatility enables researchers to pursue biomarker identification from preclinical settings through clinical trials.
How CANscript works
Read more about the CANscript platform in “Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity,” published in Nature Communications.
Human. Efficient. Multiplexed.
CANscript starts with a tumor sample taken either from a biopsy or surgical resection, and a blood sample from the same donor. The tissue sample is divided into fragments that preserve the heterogeneity of the tumor, including tumor cells, immune cells, and stromal components.
The parallel sections, along with the autologous plasma, are then placed into wells coated with indication and grade-matched matrix proteins, recapitulating the tumor microenvironment.
As a result, multiple therapeutic options can be weighed simultaneously and with a high degree of accuracy, allowing researchers to understand mechanism of action and to prioritize the most promising candidates for advancement into clinical trials.